Study reveals disparities in heart failure diagnosis within clinical practices
Many heart failure diagnoses may be missed in a primary care setting. Women, Black adults and individuals with lower net worth are significantly more likely to be diagnosed with heart failure in an acute care setting such as the emergency room or during a hospitalization, even if they reported symptoms of heart failure during a routine, outpatient health care appointment during the previous six months, according to new research published today in
Circulation: Heart Failure, an American Heart Association journal.
This national study raises concerns that many heart failure diagnoses may be missed in a primary care setting. Our results suggest acute care diagnosis rates for heart failure may be reduced if signs and symptoms of heart failure are more closely assessed in a primary care setting, particularly among women and Black adults.
High Deductibles Keeping Chest-Pain Patients Out of the ED? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
May 27, 2021
Adding dapagliflozin to standard heart failure therapies provides “intermediate value” for American patients who have heart failure with reduced ejection fraction (HFrEF), a new cost-effectiveness analysis suggests at odds with earlier analyses that suggested the cost per quality-adjusted life-year (QALY) would be below the accepted $50,000 cutoff.
That’s because earlier studies, focused on settings outside the United States, considered both the “markedly lower” costs of the drug in countries like the United Kingdom, Germany, and Spain, as well as the lower overall healthcare costs in those nations, investigators led by Justin Parizo, MD (Stanford University, CA), say.
“Cost-effectiveness analyses are inherently tied to the society in which they’re evaluated,” senior author Alexander Sandhu, MD (Stanford University), explained to TCTMD. “While the clinical benefits might be quite similar across different contexts and populations, the costs of therapy